Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994 (DrugBank: Alemtuzumab)
21 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 0 |
15 | 封入体筋炎 | 0 |
19 | ライソゾーム病 | 0 |
20 | 副腎白質ジストロフィー | 0 |
43 | 顕微鏡的多発血管炎 | 0 |
44 | 多発血管炎性肉芽腫症 | 0 |
46 | 悪性関節リウマチ | 1 |
49 | 全身性エリテマトーデス | 0 |
51 | 全身性強皮症 | 0 |
60 | 再生不良性貧血 | 0 |
62 | 発作性夜間ヘモグロビン尿症 | 0 |
63 | 特発性血小板減少性紫斑病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
85 | 特発性間質性肺炎 | 0 |
96 | クローン病 | 0 |
164 | 眼皮膚白皮症 | 0 |
234 | ペルオキシソーム病(副腎白質ジストロフィーを除く。) | 0 |
283 | 後天性赤芽球癆 | 0 |
284 | ダイアモンド・ブラックファン貧血 | 0 |
285 | ファンコニ貧血 | 0 |
326 | 大理石骨病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2010-021146-22-GB (EUCTR) | 23/10/2012 | 25/10/2012 | Alemtuzumab and rheumatoid arthritis - a study to look at the function of the immune system | Alemtuzumab and rheumatoid arthritis - an immunisation study - Alemtuzumab and rheumatoid arthritis - an immunisation study | Rheumatoid Arthritis MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994; manufacturerd by Cambridge Therapeutic Antibody Centre, Burroughs Wellcome, Glaxo Wellcome) Product Name: Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994) | The Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 4 | United Kingdom |